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Introduction
Niemann-Pick disease type C (NPC) is a fatal neurodegenerative condition caused by genetic mutations of the NPC1 (Chr. 18q11.2) or NPC2 (Chr. 14q24.3) genes that encode the NPC1 and NPC2 proteins, respectively [1, 2] . Clinically, NPC1 and NPC2 dysfunctions result in an identical condition, with NPC1 mutations accounting for nearly 95% of the reported cases and NPC2
mutations only reported in a small number of families [3] . Anatomically, the cerebellum is the most susceptible region to early neurodegeneration, marked by the progressive loss of cerebellar Purkinje neurons and corresponding early onset of cerebellar symptoms [3, 4] . Therefore, the majority of past and current research efforts are focused on elucidating the biological and pathological role of NPC1 in cerebellar degeneration. However, to date, the precise functions of NPC1 and NPC2 still remain incompletely understood, posing a challenge to understanding the pathogenesis and the mechanisms driving the progression of NPC neurodegeneration. In humans and various models of NPC, previously characterized cellular dysfunctions include: endosomal lipid sequestration [5] , neuroinflammation [6] [7] [8] , dysregulated calcium signaling [9] , mitochondrial dysfunction [10] , increased oxidative stress [11] , amyloid-beta aggregation [12] , and tau-neurofibrillary tangles [13] . While the current lipid-targeting therapeutic efforts report some clinical benefits, there is no FDA-approved therapy for NPC to date [14] .
Previous studies in animal models have demonstrated that neuroinflammation is an early finding in the neurodegenerative cascade of NPC [6, 7] . In the most widely used Npc1 -/-mice (BALB/cNctr-Npc1 miN /J), microglial activation and reactive astrocytosis have been reported as early as 2 weeks of age, significantly prior to the typical onset of neurological deficits between 7-8 weeks of age observed in this strain [7, 8] . Furthermore, recent evidence highlights that neuroinflammation is not only present prior to symptomatic onset but it is also a direct disease modifier of NPC neurodegeneration [8, [15] [16] [17] . For example, systemic delivery of general antiinflammatory drug, ibuprofen, improves the overall lifespan in the Npc1 -/-mice [15] , and sustained reduction in thalamic inflammation, as a result of neuron-specific Npc1 gene rescue, appears to mechanistically contribute to the significant increase in lifespan and delayed neurologic onset [16] .
In addition, an astrocyte-specific rescue of NPC1 leads to protection against microglial activation
and a three-fold increase in lifespan of Npc1 -/-mice [17] . Together, recent cell-specific NPC1 rescue studies highlight neuroinflammation as the pathologic convergence point of both neuronal and astrocytic NPC1 dysfunction. On the other hand, increased neuroinflammation, marked by increased cerebellar astrocytosis as a result of Amyloid Precursor Protein loss of function, leads to an accelerated neurodegenerative phenotype, including earlier onset of neurologic symptoms, reduced neuromuscular function, and significantly decreased lifespan in the Npc1 -/-mice [8] .
Taken together, targeting the early onset and sustained neuroinflammation in NPC may result in therapeutic benefits.
Nevertheless, questions still remain on the road to NPC-specific anti-inflammatory therapy. The major gap in the current understanding of NPC neuroinflammatory response is twofold: 1) the initial trigger of the inflammatory onset in the CNS milieu of early NPC and 2) the mechanisms involved in the sustained and chronic neuroinflammation that promotes pathology. To address this, we carried out a comparative genome-wide transcriptome analysis of the pre-symptomatic Npc1 
Materials and Methods
Mice and Tissue Processing
This study was approved by Loma Linda University Institutional Animal Care and Use Committee (LLU#8170041). Npc1 +/+ and Npc1 -/-littermates were generated from a breeding colony of BALB/cNctr-Npc1 miN /J from the Jackson Laboratory. Genotypes were determined as previously described [8] .
Microarray Hybridization and Transcriptome Analysis
Cerebellar samples of pre-symptomatic Npc1 -/-and age-matched Npc1 +/+ mice were sent to GenUs (GenUs Biosystems, Northbrook, IL) for RNA processing and microarray hybridization. A separate v2 GE 4x44 microarray chip was used for each sample, for a total of 6 chips (n=3 each
for Npc1 -/-and Npc1 +/+ ; males between 3 to 6 weeks; Supplementary Table 1) . Two-tailed student's t-test was used for statistical analysis. Differentially expressed genes (DEGs) were selected by both fold-change (absolute FC >1.5) and p-value (p < 0.05) cutoffs, as previously described [18] .
The transcriptome was analyzed by the Gene-Set Enrichment Analysis software (GSEA, www.broadinstitute.org/gsea), as previously described [19] using c1.Hallmark database of the Molecular Signature Databases (MSigDB, http://software.broadinstitute.org/gsea/msigdb).
Normalized enrichment score (NES) and false discovery rate (FDR) were calculated by the GSEA and FDR < 0.25 was considered significant, as recommended by the software developers [19] .
Ingenuity Pathway Analysis software (IPA, Qiagen, Redwood City CA) was utilized for molecular mapping and functional pathway analysis of the highly DEGs with priority in identifying the most affected pathways in early NPC.
Cytokine Detection
The levels of 32 cytokines in Npc1 +/+ and Npc1 -/-mouse cerebella were analyzed (3-week Npc1 +/+ ; n = 4; 2 males/2 females, 3-week Npc1 
Results
Genome-wide transcriptome analysis of pre-symptomatic NPC cerebella reveals the activation of IFN-γ-and IFN--responsive genes
In total, 387 DEGs were identified in the Npc1 -/-cerebella, of which 176 genes were upregulated and 211 genes were downregulated (Supplementary Table 2 ). We first analyzed the Npc1 -/-cerebellar transcriptome utilizing Gene-Set Enrichment Analysis (GSEA) that effectively identifies majorly affected pathways [19] . GSEA revealed that the Interferon Gamma Response gene-set was the most enriched gene-set with NES of 1.695 and FDR q-value of 0.032 (Fig. 1A) . GSEA also revealed that the Interferon Alpha Response gene-set was significantly enriched with NES of 1.519
and FDR q-value of 0.099 (Fig. 1B) . (Fig. 2) , of which 48 genes were upregulated and 12 genes were downregulated (Fig. 2) . In addition, IPA revealed that IFN- activation is upstream of 23 DEGs (Fig. 2 ). ( Fig. 3 ). Of these, Ip-10/Cxcl10, Tlr4, Tgfb1, Casp1, and Rantes/Ccl5 also co-mapped with IFN- (Fig. 3) .
IFN--and IFN--responsive DEGs in pre-symptomatic
Next, IPA revealed that 15 IFN-γ-responsive DEGs from the pre-symptomatic Npc1 -/-cerebella are involved in anti-viral response, including Tnfrsf9, Plp1, Ip-10/Cxcl10, Rantes/Ccl5, Oasl,
Stat1, Samhd1, Lcn2, Ifitm1, Ifi16, Ifit3, Mmp12, Isg15, Irf7, and Oas1 (Fig. 3 ). Of these, 9 also (Fig. 3) .
Next, IPA revealed that IFN-γ-responsive DEGs are involved in T-lymphocytes activation and chemotaxis (Fig. 3) (Fig. 3) . Seven of these IFN-γ-responsive DEGs also co-mapped with IFN- ( (Fig. 3 ).
Multiplex protein analysis of NPC cerebella highlights IFN-γ-responsive proinflammatory cytokines
Our Npc1 -/-cerebellar transcriptome results showed robust changes in innate immune genes, including various inflammatory cytokines and cytokine receptors (Table 1) , congruent with previous reports of increased mRNA levels of inflammatory cytokines in NPC [20, 21] . However, in addition to the identification of individual innate immune genes, our systematic pathway analyses revealed that a novel and atypical activation pattern of IFN--and IFN--responsive DEGs drive the four major inflammatory pathways identified in the Npc1 -/-cerebella (Figs. 1-3 ).
Therefore, we next examined the protein levels of IFN-responsive pro-inflammatory cytokines in the pre-symptomatic Npc1 -/-cerebella (3 weeks), as well as the changes in their protein levels as neurodegeneration progresses to the terminal stage (12 weeks). Specifically, three prominent IFN-γ-responsive cytokines (Table 1 ) and nine cytokines predicted as potential master regulators by Table 3) were selected for validation. We also examined the levels of 20 additional prominent inflammatory cytokines.
IPA upstream analysis (Supplementary
Of the 32 cytokines measured by the multiplex assay, at 3 weeks, interferon-gamma-induced protein 10 (IP-10/CXCL10) was the only molecule detected to be significantly elevated in the (Fig. 4B-I ).
Additionally, Interleukin-15 (IL-15) was reduced ( Fig. 4J ) and eotaxin (CCL11) and leukemia inhibitory factor (LIF) were elevated in terminal stage Npc1 -/-cerebella ( Fig. 4K & L) . Lastly, fourteen cytokines showed no significant differences between genotypes at either timepoints (Supplementary Figure 1) , and six (GM-CSF, IL-3, IL-12(p70), IL-13, LIX/CXCL5, and TNF-)
were below the detectable range of the multiplex assay.
Discussion
Neuroinflammation is an early pathologic event in NPC neurodegeneration [7, 8] , as well as a direct disease modifier of both disease onset and overall lifespan in animal models of NPC [8, [15] [16] [17] . Previous gene expression studies in NPC have reported altered expression of several innate immune genes, particularly the increased expression of the complement factors [20, 21] . However, genetic knockout of complement factors C1q and C3 do not ameliorate CNS inflammation nor rescue the overall lifespan of Npc1 -/-mice [28] , suggesting that the complement pathway does not serve a primary pathogenic role. Therefore, to date, the major inflammatory pathway that serves as the initial trigger of sustained and chronic neuroinflammation that promotes pathology remains elusive. Here, our genome-wide transcriptome analysis of highly DEGs in pre-symptomatic Npc1 Fig. 4A-I ).
IP-10/CXCL10 was significantly increased at the pre-symptomatic stage and further exacerbated in the terminal stage (Fig. 4A) . While increased Ip-10/Cxcl10 mRNA expression has been previously reported in NPC mice [21] , this is, to our knowledge, the first report providing a pathophysiological context of increased IP-10/CXCL10 protein expression related to IFN-γ signaling in pre-symptomatic and terminal stages of NPC. Functionally, IP-10/CXCL10 is a potent downstream effector of IFN-γ [22, 23] , the master regulator of the adaptive immune activation [29] . Specifically, IP-10/CXCL10 drives the chemotaxis of CXCR3+ immune cells to the site of CNS inflammation, namely CD4+ and CD8+ T-lymphocytes [23, 30] . In addition, IP-10/CXCL10 also plays a major role in the development and antigen-specific activation of T-lymphocytes [23] .
Accordingly, our IPA results highlight DEGs directly related to T-lymphocyte activation and chemotaxis in pre-symptomatic Npc1 -/-cerebella (Fig. 3) . Previously, neutralization of IP-10/CXCL10 has been shown to be protective against T-lymphocyte mediated tissue damage in both CNS [31, 32] and peripheral disorders [33] involving aberrant immune response. Therefore, targeted IP-10/CXCL10 therapy may provide beneficial outcomes in NPC.
The activation of the IFN-γ system and the early protein expression of IP-10/CXCL10 may be a key mediator of microglial activation in NPC (Figs. 3 & 4A) . Previously, direct IFN-γ-mediated expression of IP-10/CXCL10 was characterized in human microglia [25] , and microglial expression of IP-10/CXCL10 and CXCR3 (IP-10/CXCL10-receptor) have been shown to initiate glial activation and subsequent inflammatory response in spinal cord injury [34] . However, activated astrocytes are another major CNS-source of IP-10/CXCL10 [35] and neuronal secretion of IP-10/CXCL10 has also been reported [36] .
Next, the activation of IFN-γ-responsive anti-viral genes in the pre-symptomatic NPC cerebellum is particularly interesting, given the newly discovered link between NPC1 and viral infection.
NPC1 protein is directly involved in the pathogenesis of viral infection [37] [38] [39] [40] and NPC1 is also implicated in the host infection of the intracellular bacterial pathogen, Mycobacterium tuberculosis [41] . IFN-γ plays a crucial role in activating the adaptive immune response [29] and defects in IFN-γ signaling result in refractory viral and mycobacterial infections [29, 42] . Furthermore, a defect in IP-10/CXCL10 also results in similar refractory viral and bacterial infections [23, 30] , As expected, the terminal stage Npc1 -/-cerebella also displayed pleiotropic differential expression of IL-15, eotaxin/CCL11, and LIF (Fig. 4J-L) . The reduction in IL-15, an IFN-γ-and IFN--responsive cytokine, is contrary to previous reports in the periphery [45, 46] , and warrants further
investigation in a CNS disease model. The increase in eotaxin/CCL11 may be linked to the activation of IFN-γ which potentiates eotaxin/CCL11 expression in the periphery [47] . Lastly, the increase in LIF (Fig. 4L) , a pleiotropic cytokine upregulated following the induction IL-1α [48] , is potentially a downstream effect of the significant IL-1α activation in the terminal stage Npc1 -/-cerebella (Fig. 4H ).
In conclusion, we report an atypical activation pattern of IFN-γ-and IFN--responsive genes and proteins in the Npc1 -/-mouse cerebella. Subsequently, we propose a mechanism, illustrated in figure 5 , in which the aberrant activation of IFN- and IFN- downstream signaling drives the proinflammatory responses involving microglia, astrocytes, anti-viral mechanisms, and peripheral leukocytes (i.e. T-lymphocytes) in pre-symptomatic Npc1 -/-cerebella. Whether this mechanism also occurs in brain regions that are less vulnerable, but ultimately also affected by NPC disease, such as the hippocampus, remains to be determined. Nevertheless, given that lipid abnormalities are present at an early stage throughout the NPC brain [49] , whereas astrocytosis and microglia dysfunction in regions such as the hippocampus is relatively attenuated [50] , it is plausible that a delayed onset of aberrant IFN downstream signaling in these regions may account for the early and prominent role of cerebellar pathology in the disease. and p < 0.05). *Genes included in the protein validation by multiplex cytokine/chemokine assay.
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